• Share results from a multicentre Phase 2 trial in adult B-ALL, marking the first centralised EMA commercialisation request for a CAR-T product
• Compare real-world evidence of approved CAR-T and off-label B-cell lymphoma treatments to assess long-term efficacy and safety
• Discuss insights from Hospital Clinic Barcelona’s experience as one of Europe’s earliest CAR-T/TCR treatment centres

New Data